High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy

Table 2

Uni- and multivariate analysis of impacts of various parameters on overall survival from diagnosis in patients with metastatic prostate cancer.

Variables	Univariate			Multivariate
	HR	95% CI		HR	95% CI
Age	1.009	0.975–1.043	0.99	1.02	0.970–1.073	0.4208
Gleason score	1.804	1.273–2.560	0.0009	1.34	0.681–2.611	0.3918
PSA at diagnosis	1	0.999–1.000	0.973	0.999	0.9991–0.9996	0.0247
PSA nadir	1.002	1.000–1.003	0.0228	1.022	1.003–1.042	0.0227
ALP at diagnosis	1.0002	1.0000–1.0004	0.007	0.999	0.9994–1.0001	0.4046
ALP flare ratio	1.151	1.012–1.007	0.0337	1.885	1.374–2.647	<0.0001
LDH at diagnosis	1.005	1.002–1.007	0.0003	1.004	1.0004–1.0088	0.0311
Hemoglobin	0.911	0.812–1.033	0.1441	0.859	0.6943–1.0781	0.1847
Testosterone	0.932	0.724–1.199	0.587	0.8251	0.6033–1.1309	0.229

ART: androgen receptor targeted therapy, PSA: prostate-specific antigen, LDH: lactate dehydrogenase, ALP: alkaline phosphatase.